Roflumilast Approved by FDA for Treating COPD

by Kathy Jones on  March 3, 2011 at 7:48 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

The US Food and Drug Administration has approved the use of Roflumilast in the treatment of chronic obstructive pulmonary disease (COPD) which involves chronic bronchitis.
 Roflumilast Approved by FDA for Treating COPD
Roflumilast Approved by FDA for Treating COPD

The drug is marketed under the brand name of Daliresp by New York based Forest Laboratories and treats COPD by blocking phosphodiesterase type 4 enzyme. COPD is a form of lung disease usually caused by smoking and is characterized by chronic cough and excessive phlegm.

Clinical trials of the drug involved more than 1500 patients older than 40 years of age, all of whom were suffering from chronic bronchitis during the prior year.

The FDA said that while the drug can be used to treat the flares of COPD, it has not yet approved for the treatment of another form of the disease known as primary emphysema.



Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Pneumoconiosis Pulmonary Arterial Hypertension 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive